A case of omalizumab as a successful treatment for telangiectasia macularis eruptiva perstans

Australas J Dermatol. 2022 Feb;63(1):102-104. doi: 10.1111/ajd.13674. Epub 2021 Jul 27.


Treatment for telangiectasia macularis eruptiva perstans (TMEP) is often challenging due to lack of an established first-line therapy and as such is primarily focused on symptomatic relief. Omalizumab shows promise as a potential therapy for mast cell disorders; however, its efficacy in TMEP is yet to be established. This case describes a 72-year-old woman with chronic refractory TMEP achieving symptomatic remission within 4 months of commencing omalizumab therapy.

Keywords: biologic drugs; biologics; immunology; mast cell activation syndrome; mastocytosis.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Dermatologic Agents / therapeutic use*
  • Female
  • Humans
  • Mastocytosis, Cutaneous / drug therapy*
  • Omalizumab / therapeutic use*


  • Dermatologic Agents
  • Omalizumab

Supplementary concepts

  • Telangiectasia macularis eruptiva perstans